drugset
drugset / Trial / NCT01009957

Everolimus on CKD Progression in ADPKD Patients

NCT01009957 ↗

Phase 2/3 Terminated 71 enrolled A. Manzoni Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The study will evaluate whether the administration of everolimus (1.5 mg/day) can slow down the progression of CKD in ADPKD patients.

Timeline

Start
2008-06
Primary completion
2014-01
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule 0.75 mg —

Indications

autosomal dominant polycystic kidney disease